http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Xunxing Guan (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Zhenyu He,San-Gang Wu,Juan Zhou,Fengyan Li,Jiayan Sun,Qin Lin,Huanxin Lin,Xunxing Guan 한국유방암학회 2014 Journal of breast cancer Vol.17 No.3
Purpose: Several accelerated partial breast irradiation (APBI)techniques are being investigated in patients with early-stagebreast cancer. The present study evaluated the feasibility, earlytoxicity, initial efficacy, and cosmetic outcomes of acceleratedpartial breast intensity-modulated radiotherapy (IMRT) for Chinesefemale patients with early-stage breast cancer after breastconservingsurgery. Methods: A total of 38 patients met the inclusioncriteria and an accelerated partial breast intensity-modulatedradiotherapy (APBI-IMRT) plan was designed for each patient. The prescription dose was 34 Gy in 10 fractions, 3.4 Gy per fraction,twice a day, in intervals of more than 6 hours. Results: Of the38 patients, six patients did not meet the planning criteria. Theremaining 32 patients received APBI-IMRT with a mean targetvolume conformity index of 0.67 and a dose homogeneity indexof 1.06. The median follow-up time was 53 months and no localrecurrence or distant metastasis was detected. The most commonacute toxicities observed within 3 months after radiotherapywere erythema, breast edema, pigmentation, and pain in the irradiatedlocation, among which 43.8%, 12.5%, 31.3%, and28.1% were grade 1 toxicities, respectively. The most commonlate toxicities occurring after 3 months until the end of the followupperiod were breast edema, pigmentation, pain in the irradiatedlocation, and subcutaneous fibrosis, among which 6.2%,28.1%, 21.9%, and 37.5% were grade 1 toxicities, respectively. Thirty-one patients (96.8%) had fine or excellent cosmetic outcomes,and only one patient had a poor cosmetic outcome. Conclusion: It is feasible for Chinese females to receive APBIIMRTafter breast conserving surgery. The radiotherapeutic toxicityis acceptable, and both the initial efficacy and cosmeticoutcomes are good.
-
Ge Wen,Jin-Shan Zhang,Yu-Jing Zhang,Yu-Jia Zhu,Xiao-Bo Huang,Xunxing Guan 한국유방암학회 2016 Journal of breast cancer Vol.19 No.2
Purpose: This study was designed to investigate the relationship between molecular subtype and locoregional recurrence (LRR) in patients with early-stage breast cancer with 1–3 positive axillary lymph nodes (ALNs) and improve the individualized indications for postmastectomy radiotherapy (PMRT). Methods: The records of 701 patients with pT1-2N1M0 breast cancer who did not undergo PMRT were retrospectively analyzed. Tumors were subclassified as follows: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and basal-like subtypes. Multivariate Cox analysis was used to determine the risk of LRR associated with the different subtypes and to adjust for clinicopathologic factors. Results: Luminal A, luminal B, HER2- enriched, and basal-like subtypes accounted for 51.2%, 28.0%, 8.1%, and 12.7% of cases, respectively. The median follow-up duration was 67 months (range, 9–156 months). Univariate analysis revealed that, compared with the luminal A subtype, the HER2-enriched and basal-like subtypes were associated with significantly higher 5-year LRR rates (5.6% vs. 21.6% and vs.15.7% respectively; p=0.002 each), lower 5-year LRR-free survival (LRFS) rates (90.6% vs. 73.8% and 78.5%, respectively; p=0.001 each), and poorer 5-year breast cancer-specific survival (BCSS) rates (93.7% vs. 82.2% [p=0.002] and 84.9% [p=0.001], respectively). Multivariate analysis revealed that the HER2-enriched and basal-like subtypes, age ≤35 years, a medial tumor, and pT2 stage were poor prognostic factors for LRR and LRFS; furthermore, 2 to 3 positive ALNs represented an independent prognostic factor affecting LRR. The 10-year LRR rates of patients with 0, 1, 2, 3, and 4 risk factors were 1.0%, 6.9%, 14.3%, 30.4%, and 54.3%, respectively (p<0.001); the 10-year BCSS rates were 86.6%, 88.5%, 84.4%, 79.7%, and 38.8%, respectively (p<0.001). Conclusion: Molecular subtyping allows for individualized evaluation of LRR risk in patients with pT1-2N1M0 breast cancer. PMRT should be recommended for patients with ≥3 LRR risk factors.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
